68Ga-DOTA-FAPI-04在骨与关节中的摄取增高:转移及其他
该研究回顾性分析129例68Ga-FAPI PET/MR或PET/CT扫描,发现82例(63.57%)骨与关节存在摄取增高,共295个病灶,其中恶性转移94个(31.9%),良性病灶201个(68.1%)。骨转移灶平均SUVmax显著高于良性病变(7.14±4.33 vs. 3.57±1.60, p<0.001),但存在重叠,不能据此鉴别良恶性。
要点
- 68Ga-FAPI在骨转移和多种良性骨关节病变中均可摄取增高,脊柱、肩关节、牙槽嵴和骨盆为常见部位。
- 骨转移灶SUVmax均值显著高于良性病变,但数值重叠,无法单独用于鉴别诊断。
- 在同时接受两种检查的患者中,68Ga-FAPI PET识别的病灶数多于18F-FDG PET(104 vs. 48)。
核心结论
- 68Ga-FAPI在骨转移和部分良性骨关节疾病中均有摄取,虽骨转移摄取常更高,但不能用于区分良恶性。
- 68Ga-FAPI PET有潜力定位和评估骨与关节的恶性及良性病变范围。
研究设计与样本
- 回顾性分析2020年6月1日至2021年2月20日在本中心进行的129例68Ga-FAPI PET/MR或PET/CT扫描。
- 记录骨与关节摄取增高灶的数量、位置和SUVmax,分为恶性(转移)和良性病变,并比较其中同时有68Ga-FAPI和18F-FDG PET患者的病灶检出。
主要发现
- 82例(63.57%)发现骨与关节摄取增高,共295个病灶,恶性转移94个(31.9%),良性201个(68.1%)。
- 良性病变包括骨纤维异常增殖13个、退行性骨病48个、牙周炎33个、关节炎56个、其他炎症或创伤相关异常51个。
- 脊柱、肩关节、牙槽嵴和骨盆是最常累及部位;骨转移主要分布于脊柱、骨盆和肋骨;牙周炎和关节炎具有部位特异性。
- 骨转移灶平均SUVmax显著高于良性病变(7.14±4.33 vs. 3.57±1.60, p<0.001),但存在重叠;良性病变亚组间SUVmax差异有统计学意义(p<0.001),牙周炎摄取较高(4.45±1.17)。
- 在同时接受两种检查的患者中,68Ga-FAPI PET识别病灶数多于18F-FDG PET(104 vs. 48),且摄取更高。
临床怎么用
- 68Ga-FAPI PET可用于骨与关节病变的定位和范围评估,但需结合临床和其他影像鉴别良恶性,不能仅凭SUVmax判断。
- 阅片时应关注牙周炎、关节炎、退行性骨病等良性病变的生理性或炎性摄取,避免误判为转移。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the uptake of 68Gallium-labelled fibroblast activation protein inhibitor (68Ga-FAPI) in the bones and joints for better understanding of the role of 68Ga-FAPI PET in benign and malignant bone lesions and joint diseases. METHODS: All 129 68Ga-FAPI PET/MR or PET/CT scans from June 1, 2020, to February 20, 2021, performed at our PET center were retrospectively reviewed. Foci of elevated 68Ga-FAPI uptake in the bones and joints were identified. All lesions were divided into malignant and benign diseases. Benign lesions included osteofibrous dysplasia, periodontitis, degenerative bone diseases, arthritis, and other inflammatory or trauma-related abnormalities. The number, locations, and SUVmax of all lesions were recorded and analyzed. The detectability of 68Ga-FAPI PET and 18F-FDG PET in patients who had two scans was also compared. RESULTS: Elevated uptake of 68Ga-FAPI in/around the bones and joints was found in 82 cases (63.57%). A total of 295 lesions were identified, including 94 (31.9%) malignant lesions (all were metastases) and 201 (68.1%) benign lesions. The benign lesions consisted of 13 osteofibrous dysplasia, 48 degenerative bone disease, 33 periodontitis, 56 arthritis, and 51 other inflammatory or trauma-related abnormalities. The spine, shoulder joint, alveolar ridge, and pelvis were the most commonly involved locations. Bone metastases were mainly distributed in the spine, pelvis, and ribs. Among benign diseases, periodontitis and arthritis are site-specific. The mean SUVmax of bone metastases was significantly higher than that of benign diseases (7.14 ± 4.33 vs. 3.57 ± 1.60, p < 0.001), but overlap existed. The differences in SUVmax among subgroups of benign diseases were statistically significant (p < 0.001), with much higher uptake in periodontitis (4.45 ± 1.17). 68Ga-FAPI PET identified much more lesions than 18F-FDG PET (104 vs. 48) with higher uptake value. CONCLUSION: 68Ga-FAPI accumulated in both bone metastases and some benign diseases of the bones and joints. Although the uptake of 68Ga-FAPI was often higher in bone metastases, this finding cannot be used to distinguish between benign and malignant lesions. 68Ga-FAPI PET also has the potential to locate and evaluate the extent of both malignant tumor and benign diseases in bones and joints. TRIAL REGISTRATION: NCT04554719, NCT04605939. Registered September 8, 2020 and October 25, 2020-retrospectively registered, http://clinicaltrails.gov/show/NCT04554719 ; http://clinicaltrails.gov/show/NCT04605939.
引用
- Qin C, Song Y, Liu X, et al. Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond. Eur J Nucl Med Mol Imaging. 2021. PMID: 34241652. doi:10.1007/s00259-021-05472-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。